LFG
AXSM icon

Larson Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Larson Financial Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11K Sell
65
-4
-6% -$691 ﹤0.01% 2192
2025
Q4 		$12.6K Buy
69
+25
+57% +$3.49K ﹤0.01% 1982
2025
Q3 		$5.34K Buy
44
+43
+4,300% +$4.84K ﹤0.01% 2333
2025
Q2 		$104 Hold
1
– – ﹤0.01% 3158
2025
Q1 		$117 Buy
+1
New +$114 ﹤0.01% 2885

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Larson Financial Group's AXSM Position: Q1 2026 in Review

Larson Financial Group reduced its Axsome Therapeutics (AXSM) stake by 5.8% in Q1 2026, selling an estimated $691 and leaving 65 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

Larson Financial Group first reported a position in AXSM in Q1 2025 and has held it in 5 quarters since. The position peaked at $12.6K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Larson Financial Group held 65 shares of Axsome Therapeutics worth $11K as of Q1 2026.
  • Larson Financial Group sold 4 Axsome Therapeutics shares in Q1 2026, an estimated $691.
  • Axsome Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #2192 holding.
  • Larson Financial Group first reported a position in Axsome Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Axsome Therapeutics position peaked at $12.6K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.